Randy H. Thurman - Sep 29, 2022 Form 4 Insider Report for TFF Pharmaceuticals, Inc. (TFFP)

Role: Director
Signature: /s/ Randy Thurman, by Kirk Allen Coleman, as Attorney-in-Fact
Stock symbol: TFFP
Transactions as of: Sep 29, 2022
Transactions value $: -$72,056
Form type: 4
Date filed: 9/30/2022, 05:20 PM
Previous filing: Mar 24, 2022
Next filing: Mar 31, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TFFP	Common Stock	Options Exercise	$101K	+40.3K		$2.50^*	40.3K	Sep 29, 2022	Direct
transaction	TFFP	Common Stock	Sale	-$173K	-40.3K	-100%	$4.29^*	0	Sep 29, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TFFP	Stock Options (Right to Buy)	Options Exercise	$0	-40.3K	-32.22%	$0.00	84.7K	Sep 29, 2022	Common Stock	40.3K	$2.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
F2	The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.

Content

The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.